Thursday, September 07, 2017 1:51:01 PM
My view has been consistent. CHEMOSAT is operational and working in EU; management is completely incompetent and unable to maximize its potential. This company will get b/o because of the value of the intellectual capital. It will not be JV because no one in their right mind wants to work with this leadership IMO.
If somehow you took my view and lost money; sorry man but not many lost more than me (60k); I made back almost 1/2 that in day trades and also was able to buy back in lower. But that 2nd R/S fiasco caught everyone by surprise. If this R/S passes and the stock dumps to .02 - guess what; I lose with holding 2M plus shares. However, I won't blame a single other person as that is just weak IMO; I'm an adult and make my own decisions. I do value DD and that is why I come to these boards and post on ST.
Can I be wrong about B/K? Certainly, but wouldn't you agree that would ONLY occur if there are no potential companies willing to buy them out or to take over. If that is so then I made a miscalculation of a lifetime because obviously, their product isn't worth what we thought. You say this could easily be a 1B company which is a far cry of 15M you posted this morning. Let's meet in the middle at 500m. That is 1.00 a share and I am sure everyone here would take that in a heartbeat. That is what I am looking for
Now take a step back and note that CHEMOSAT has had over 100 successful treatments in both the UK and Germany and is just opening up in Dutch and Austrailian markets. They have 510k pending and trial news due this month. I have to believe BK talk is entirely pre-mature.
If somehow you took my view and lost money; sorry man but not many lost more than me (60k); I made back almost 1/2 that in day trades and also was able to buy back in lower. But that 2nd R/S fiasco caught everyone by surprise. If this R/S passes and the stock dumps to .02 - guess what; I lose with holding 2M plus shares. However, I won't blame a single other person as that is just weak IMO; I'm an adult and make my own decisions. I do value DD and that is why I come to these boards and post on ST.
Can I be wrong about B/K? Certainly, but wouldn't you agree that would ONLY occur if there are no potential companies willing to buy them out or to take over. If that is so then I made a miscalculation of a lifetime because obviously, their product isn't worth what we thought. You say this could easily be a 1B company which is a far cry of 15M you posted this morning. Let's meet in the middle at 500m. That is 1.00 a share and I am sure everyone here would take that in a heartbeat. That is what I am looking for
Now take a step back and note that CHEMOSAT has had over 100 successful treatments in both the UK and Germany and is just opening up in Dutch and Austrailian markets. They have 510k pending and trial news due this month. I have to believe BK talk is entirely pre-mature.
Recent DCTH News
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/15/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:47:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:23:52 PM
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference • Business Wire • 05/12/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:12:12 PM
- Delcath Systems Reports First Quarter 2026 Results and Business Highlights • Business Wire • 05/07/2026 12:00:00 PM
- Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 • Business Wire • 05/07/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Delcath Systems to Host First Quarter 2026 Earnings Call • Business Wire • 04/23/2026 12:30:00 PM
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:06:06 PM
